{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:39:02Z","timestamp":1793619542089,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004286","name":"Santen","doi-asserted-by":"publisher","award":["IST_RKM008"],"award-info":[{"award-number":["IST_RKM008"]}],"id":[{"id":"10.13039\/501100004286","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and objective<\/jats:title>\n                <jats:p>To evaluate the safety and efficacy of intravitreal sirolimus for persistent, exudative age-related macular degeneration (AMD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This institutional review board approved, registered (NCT02357342), prospective, subject-masked, single center, randomized controlled trial in subjects with persistent, exudative Age-related macular degeneration compared intravitreal sirolimus monotherapy (every 2\u00a0months) versus monthly anti-vascular endothelial growth factor (VEGF) over six months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>20 subjects were randomized to each arm of the trial. Upon completion of the trial 20 patients were analyzed in the control (anti-vascular endothelial growth factor) group and 17 patients were analyzed in the treatment (sirolimus) group. On average, subjects had 33 previous anti-VEGF injections prior to entry. The primary end-point, mean central subfield thickness (CST), increased by 20\u00a0\u00b5m in the anti-vascular endothelial growth factor group and decreased by 40\u00a0\u00b5m in the sirolimus group (<jats:italic>p<\/jats:italic>\u2009=\u2009<jats:italic>0.03<\/jats:italic>). Visual acuity outcomes were similar between groups. Serious ocular adverse events in the sirolimus group included one subject each with anterior uveitis, central retinal artery occlusion and subretinal hemorrhage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Monotherapy with intravitreal sirolimus for subjects with persistent, exudative age-related macular degeneration appears to have a limited positive anatomic benefit. The presence of adverse events in the experimental group merits further evaluation, potentially as an adjuvant therapy.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> This trial was registered with the clinicaltrials.gov, NCT02357342, and was approved by the institutional review board at Advarra. Funding was provided by an investigator-initiated grant from Santen. Santen played no role in the design or implementation of this study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40942-021-00281-0","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T17:20:26Z","timestamp":1613582426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intravitreal sirolimus for persistent, exudative age-related macular degeneration: a Pilot Study"],"prefix":"10.1186","volume":"7","author":[{"given":"Robert J.","family":"Minturn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bracha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret J.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Harless","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-1846","authenticated-orcid":false,"given":"Raj K.","family":"Maturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"281_CR1","doi-asserted-by":"crossref","unstructured":"CATT Research Group, Martin DF, Maguire, Maureen, Ying, Gui-Shuang, Grunwald, Juan E, Fine, Stuart L, et al. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","DOI":"10.1056\/NEJMoa1102673"},{"issue":"7","key":"281_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying G, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388\u201398.","journal-title":"Ophthalmology"},{"issue":"6","key":"281_CR3","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/IAE.0000000000000465","volume":"35","author":"C Gianniou","year":"2015","unstructured":"Gianniou C, Dirani A, Jang L, Mantel I. Refractory intraretinal or subretina fluid in neovascular age-related macular degeneration treated with intravitreal ranizubimab: functional and structural outcome. RETINA. 2015;35(6):1195\u2013201.","journal-title":"RETINA"},{"issue":"4","key":"281_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","volume":"123","author":"S Sharma","year":"2016","unstructured":"Sharma S, Toth CA, Daniel E, Grunwald JE, Maguire MG, Ying G-S, et al. Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(4):865\u201375.","journal-title":"Ophthalmology"},{"issue":"9","key":"281_CR5","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/j.ophtha.2015.05.042","volume":"122","author":"AS Willoughby","year":"2015","unstructured":"Willoughby AS, Ying G, Toth CA, Maguire MG, Burns RE, Grunwald JE, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(9):1846\u201353.","journal-title":"Ophthalmology"},{"issue":"10","key":"281_CR6","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/IAE.0b013e3181e7978e","volume":"30","author":"RB Nussenblatt","year":"2010","unstructured":"Nussenblatt RB, Byrnes G, Sen HN, Yeh S, Faia L, Meyerle C, et al. A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina. 2010;30(10):1579\u201387.","journal-title":"Retina"},{"issue":"3","key":"281_CR7","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/S0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc. 2003;35(3):S7-14.","journal-title":"Transplant Proc"},{"issue":"12","key":"281_CR8","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1248\/bpb.b17-00475","volume":"40","author":"T Nakahara","year":"2017","unstructured":"Nakahara T, Morita A, Yagasaki R, Mori A, Sakamoto K. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in pathological ocular angiogenesis. Biol Pharm Bull. 2017;40(12):2045\u20139.","journal-title":"Biol Pharm Bull"},{"key":"281_CR9","first-page":"964","volume":"10","author":"NS Dejneka","year":"2004","unstructured":"Dejneka NS, Kuroki AM, Fosnot J, Tang W, Tolentino MJ, Bennett J. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice. Mol Vis. 2004;10:964\u201372.","journal-title":"Mol Vis"},{"issue":"2","key":"281_CR10","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.ajpath.2012.04.018","volume":"181","author":"NG Kolosova","year":"2012","unstructured":"Kolosova NG, Muraleva NA, Zhdankina AA, Stefanova NA, Fursova AZ, Blagosklonny MV. Prevention of age-related macular degeneration-like retinopathy by rapamycin in rats. Am J Pathol. 2012;181(2):472\u20137.","journal-title":"Am J Pathol"},{"issue":"5","key":"281_CR11","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1089\/jop.2011.0226","volume":"28","author":"S Mudumba","year":"2012","unstructured":"Mudumba S, Bezwada P, Takanga H, Hosoi K, Tsuboi T, Udea K, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocular Pharmacol Ther. 2012;28(5):507\u201314.","journal-title":"J Ocular Pharmacol Ther"},{"issue":"1","key":"281_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1590\/S0004-27492009000100004","volume":"72","author":"RP Manzano","year":"2009","unstructured":"Manzano RP, Peyman GA, Khan P, Kivilcim M, Chevez-Barrios P, Takahashi W. Testing intravitreal toxicity of rapamycin in rabbit eyes. Arq Bras Oftalmol. 2009;72(1):18\u201322.","journal-title":"Arq Bras Oftalmol."},{"issue":"11","key":"281_CR13","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/j.ophtha.2016.07.029","volume":"123","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, et al. Intravitreal sirolimus for noninfectious uveitis: a phase III Sirolimus Study Assessing Double-masKed Uveitis TReAtment (SAKURA). Ophthalmology. 2016;123(11):2413\u201323.","journal-title":"Ophthalmology"},{"issue":"8","key":"281_CR14","first-page":"517","volume":"58","author":"QD Nguyen","year":"2017","unstructured":"Nguyen QD, Merrill P, Clark WL. Efficacy and safety results from the SAKURA program: two phase III studies of intravitreal sirolimus every other month for non-infectious uveitis of the posterior segment. Invest Ophthalmol Vis Sci. 2017;58(8):517\u2013517.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"281_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2307\/2533558","volume":"53","author":"MG Kenward","year":"1997","unstructured":"Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53(3):983.","journal-title":"Biometrics"},{"issue":"1","key":"281_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.22237\/jmasm\/1177992420","volume":"6","author":"MA Padilla","year":"2007","unstructured":"Padilla MA, Algina J. Type I error rates of the Kenward-Roger adjusted degree of freedom F-test for a split-plot design with missing values. J Mod Appl Stat Methods. 2007;6(1):66\u201380.","journal-title":"J Mod Appl Stat Methods"},{"issue":"7432","key":"281_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature11861","volume":"493","author":"SC Johnson","year":"2013","unstructured":"Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493(7432):338\u201345.","journal-title":"Nature"},{"key":"281_CR18","first-page":"31","volume":"13","author":"S Sudarsanam","year":"2010","unstructured":"Sudarsanam S, Johnson D. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 2010;13:31\u201340.","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"20","key":"281_CR19","doi-asserted-by":"publisher","first-page":"3589","DOI":"10.1242\/jcs.051011","volume":"122","author":"M Laplante","year":"2009","unstructured":"Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci. 2009;122(20):3589\u201394.","journal-title":"J Cell Sci"},{"issue":"2","key":"281_CR20","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/j.1549-8719.2009.00012.x","volume":"17","author":"DD Kim","year":"2010","unstructured":"Kim DD, Kleinman DM, Kanetaka T, Gerritsen ME, Nivaggioli T, Weber D, et al. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation. 2010;17(2):128\u201336.","journal-title":"Microcirculation"},{"issue":"7448","key":"281_CR21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature12122","volume":"497","author":"H Yang","year":"2013","unstructured":"Yang H, Rudge DG, Koos JD, Vaidialingam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature. 2013;497(7448):217\u201323.","journal-title":"Nature"},{"issue":"2","key":"281_CR22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"3","key":"281_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/nrm3757","volume":"15","author":"M Shimobayashi","year":"2014","unstructured":"Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"281_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","volume":"4","author":"J Karar","year":"2011","unstructured":"Karar J, Maity A. PI3K\/AKT\/mTOR pathway in angiogenesis. Front Mol Neurosci. 2011;4:51.","journal-title":"Front Mol Neurosci"},{"issue":"8","key":"281_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1096\/fj.01-0658com","volume":"16","author":"R Humar","year":"2002","unstructured":"Humar R, Kiefer FN, Berns H, Resink TJ, Battegay EJ. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J. 2002;16(8):771\u201380.","journal-title":"FASEB J"},{"issue":"2","key":"281_CR26","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm0202-128","volume":"8","author":"M Guba","year":"2002","unstructured":"Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128\u201335.","journal-title":"Nat Med"},{"issue":"5","key":"281_CR27","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.oret.2017.08.015","volume":"2","author":"G Gensler","year":"2018","unstructured":"Gensler G, Clemons TE, Domalpally A, Danis RP, Blodi B, Wells J, et al. Treatment of geographic atrophy with intravitreal sirolimus: the age-related eye disease study 2 ancillary study. Ophthalmol Retina. 2018;2(5):441\u201350.","journal-title":"Ophthalmol Retina"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40942-021-00281-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-021-00281-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T17:36:18Z","timestamp":1613583378000},"score":1,"resource":{"primary":{"URL":"https:\/\/journalretinavitreous.biomedcentral.com\/articles\/10.1186\/s40942-021-00281-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1186\/s40942-021-00281-0","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"14 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was IRB approved by Advarra and consent was received from all subjects for participation in this study. The study strictly adhered to the Health Insurance Portability and Accountability Act and all of the tenants of the Declaration of Helsinki. Finally, this study was registered and approved by the Food and Drug Administration under the identification number NCT02357342.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent has been obtained for use of all subject images as a part of the institutional consent for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Each author\u2019s conflict of interests both financial and nonfinancial are enumerated below:Robert Minturn, Peter Bracha, Maggie Klein, Ashley M Harless: None.Jay Chhablani: Research support through Allergan, Novartis, OD-OS.Raj K Maturi: Research support through Allergan, Allegro, GlaxoSmithKline, Genentech and Santen. Consulting agreement with Santen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}